We read with great interest the recently published study by Malijan et al. investigating the effects of empagliflozin on urinary biomarkers (1). The authors reported a marked reduction in urinary uromodulin (uUMOD) levels (63%) in patients treated with empagliflozin and postulated that up to 19% of the favorable effect on the estimated glomerular filtration rate slope could be mediated by the decrease in uUMOD.